<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02335632</url>
  </required_header>
  <id_info>
    <org_study_id>EPAH</org_study_id>
    <nct_id>NCT02335632</nct_id>
  </id_info>
  <brief_title>Effect of Probiotics on Gut-Liver Axis of Alcoholic Hepatitis</brief_title>
  <official_title>Effect of Probiotics on Gut-Liver Axis of Alcoholic Hepatitis</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Chuncheon Sacred Heart Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Chuncheon Sacred Heart Hospital</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Background/Aims:&#xD;
&#xD;
      The investigators explored the therapeutic effects of probiotics in patients with AH.&#xD;
&#xD;
      Methods:&#xD;
&#xD;
      Between December 2012 and January 2015, the investigators conducted a 7-day,&#xD;
      double-controlled, randomized, prospective clinical trial comparing the efficacy of&#xD;
      probiotics in improving liver enzymes, LPS, pro-inflammatory cytokines, stool culture, and&#xD;
      stool Polymerase chain reaction denaturing gradient gel electrophoresis. AH was defined as an&#xD;
      aspartate aminotransferase (AST)/alanine aminotransferase (ALT) &gt; 2 and elevated AST (ALT)&#xD;
      level with an alcohol consumption history within 48 hours. Patients were randomized to&#xD;
      receive 7 days of cultured Lactobacillus rhamnosus R0011/acidophilus R0052 (120 mg/day) or&#xD;
      placebo. The levels of liver enzymes, modified Discriminant Function (mDF), LPS, and&#xD;
      pro-inflammatory cytokines, stool culture, and stool Polymerase chain reaction denaturing&#xD;
      gradient gel electrophoresis were checked at baseline and again after therapy.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Background/Aims: Alcoholic hepatitis (AH) is one of the leading causes of liver diseases.&#xD;
      Gut-derived microbial lipopolysaccharide (LPS) has been known as a central role in the&#xD;
      pathogenesis of AH. Some animal studies suggested an emerging role of probiotics in&#xD;
      restoration of the bowel flora and improving liver enzymes. We explored the therapeutic&#xD;
      effects of probiotics in patients with AH.&#xD;
&#xD;
      Methods:&#xD;
&#xD;
      Between December 2012 and January 2015, the investigators conducted a 7-day,&#xD;
      double-controlled, randomized, prospective clinical trial comparing the efficacy of&#xD;
      probiotics in improving liver enzymes, LPS, pro-inflammatory cytokines, stool culture, and&#xD;
      stool Polymerase chain reaction denaturing gradient gel electrophoresis. AH was defined as an&#xD;
      aspartate aminotransferase (AST)/alanine aminotransferase (ALT) &gt; 2 and elevated AST (ALT)&#xD;
      level with an alcohol consumption history within 48 hours. Patients were randomized to&#xD;
      receive 7 days of cultured Lactobacillus rhamnosus R0011/acidophilus R0052 (120 mg/day) or&#xD;
      placebo. The levels of liver enzymes, modified Discriminant Function (mDF), LPS, and&#xD;
      pro-inflammatory cytokines, stool culture, and stool Polymerase chain reaction denaturing&#xD;
      gradient gel electrophoresis were checked at baseline and again after therapy.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Active, not recruiting</last_known_status>
  <start_date>December 2012</start_date>
  <completion_date type="Anticipated">February 2015</completion_date>
  <primary_completion_date type="Anticipated">February 2015</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>liver enzymes</measure>
    <time_frame>7 days after probiotics</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>LPS and pro-inflammatory cytokines</measure>
    <time_frame>7 days after probiotics</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Stool culture and stool Polymerase chain reaction denaturing gradient gel electrophoresis</measure>
    <time_frame>7 days after probiotics</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">140</enrollment>
  <condition>Alcoholic Liver Disease</condition>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>For Probiotics, 7 days</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Probiotics</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Probiotics of 120 mg/day for 7days</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Probiotics (Lacidofil®)</intervention_name>
    <description>7 days of cultured Lactobacillus rhamnosus R0011/acidophilus R0052 (120 mg/day)</description>
    <arm_group_label>Probiotics</arm_group_label>
    <other_name>Lacidofil®</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>For probiotics</description>
    <arm_group_label>Placebo</arm_group_label>
    <other_name>For probiotics</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Alcoholic hepatitis (AST/ALT &gt;2 &amp; elevated AST (ALT) level&#xD;
&#xD;
          -  Alcohol &gt;60 g/day (M), &gt;40 g/day (F) during 7 days before screening&#xD;
&#xD;
          -  Last drinks: within 48 hours prior to admission)&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  viral hepatitis,&#xD;
&#xD;
          -  autoimmune hepatitis,&#xD;
&#xD;
          -  pancreatitis,&#xD;
&#xD;
          -  hemochromatosis,&#xD;
&#xD;
          -  Wilson's disease,&#xD;
&#xD;
          -  Drug-Induced Liver Injury,&#xD;
&#xD;
          -  cancer,&#xD;
&#xD;
          -  infection need for antibiotics,&#xD;
&#xD;
          -  severe AH, or&#xD;
&#xD;
          -  obesity (BMI &gt;30 kg/m2)&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <verification_date>January 2015</verification_date>
  <study_first_submitted>January 6, 2015</study_first_submitted>
  <study_first_submitted_qc>January 9, 2015</study_first_submitted_qc>
  <study_first_posted type="Estimate">January 12, 2015</study_first_posted>
  <last_update_submitted>January 26, 2015</last_update_submitted>
  <last_update_submitted_qc>January 26, 2015</last_update_submitted_qc>
  <last_update_posted type="Estimate">January 28, 2015</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Chuncheon Sacred Heart Hospital</investigator_affiliation>
    <investigator_full_name>Ki Tae Suk</investigator_full_name>
    <investigator_title>Department of Internal Medicine</investigator_title>
  </responsible_party>
  <keyword>Hepatitis</keyword>
  <keyword>Probiotics</keyword>
  <keyword>Lipopolysaccharides</keyword>
  <keyword>Cytokines</keyword>
  <keyword>Alcoholics</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hepatitis</mesh_term>
    <mesh_term>Liver Diseases</mesh_term>
    <mesh_term>Hepatitis, Alcoholic</mesh_term>
    <mesh_term>Liver Diseases, Alcoholic</mesh_term>
  </condition_browse>
  <pending_results>
    <submitted>January 28, 2016</submitted>
    <returned>February 24, 2016</returned>
    <submitted>April 27, 2016</submitted>
    <returned>June 2, 2016</returned>
    <submitted>June 24, 2018</submitted>
    <returned>July 19, 2018</returned>
    <submitted>August 10, 2020</submitted>
    <returned>August 20, 2020</returned>
  </pending_results>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

